The Aimovig Resubmission Journey: From FDA CRL to Approval
Hello Regulatory Scientists, Today, let’s explore the journey of Aimovig (erenumab) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Aimovig (erenumab) Mechanism of Action: CGRP (calcitonin gene-related peptide) receptor antagonist, which […]
The Aliqopa Resubmission Journey: From FDA CRL to Approval
Hello Regulatory Scientists, Today, let’s dive into the journey of Aliqopa (copanlisib) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Aliqopa (copanlisib) Mechanism of Action: PI3K inhibitor, which inhibits phosphatidylinositol-3-kinase, a […]
The Kevzara Resubmission Journey: From FDA CRL to Approval
Hello Regulatory Scientists, Today, let’s dive into the journey of Kevzara (sarilumab) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Kevzara (sarilumab) Mechanism of Action: IL-6 receptor antagonist, which helps reduce […]
The Imfinzi Resubmission Journey: From FDA CRL to Approval
Hello Regulatory Scientists, Today, let’s delve into the journey of Imfinzi (durvalumab) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Imfinzi (durvalumab) Mechanism of Action: PD-L1 inhibitor, which helps the immune […]
The Zepatier Resubmission Journey: From FDA CRL to Approval
Hello Regulatory Scientists, Today, let’s explore the journey of Zepatier (elbasvir/grazoprevir) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Zepatier (elbasvir/grazoprevir) Mechanism of Action: NS5A inhibitor (elbasvir) and NS3/4A protease […]
The Addyi Resubmission Journey: From FDA CRL to Approval
Hello Regulatory Scientists, Today, let’s delve into the journey of Addyi (flibanserin) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Addyi (flibanserin) Mechanism of Action: Serotonin 1A receptor agonist and […]
Navigating the FDA Complete Response Letter: The Xeljanz Resubmission Journey
Hello Regulatory Scientists, Today, let’s dive into the fascinating journey of Xeljanz (tofacitinib) from receiving an FDA Complete Response Letter (CRL) to eventual approval. This case study not only sheds light on the intricacies of regulatory processes but also offers valuable lessons for those developing drugs today. Regulatory History and Initial Submission Drug: Xeljanz (tofacitinib) […]
The Opdivo Resubmission Journey: From FDA CRL to Approval
Hello Regulatory Scientists, Today, let’s explore the journey of Opdivo (nivolumab) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Opdivo (nivolumab) Mechanism of Action: PD-1 inhibitor, which helps the immune […]
The Jardiance Resubmission Journey: From FDA CRL to Approval
Hello Regulatory Scientists, Today, let’s explore the journey of Jardiance (empagliflozin) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Jardiance (empagliflozin) Mechanism of Action: Sodium-glucose co-transporter 2 (SGLT2) inhibitor, which […]
The Zydelig Resubmission Journey: Navigating the Path to FDA Approval
Hello Regulatory Scientists, Today, let’s explore the journey of Zydelig (idelalisib) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case studyprovides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Zydelig (idelalisib)Mechanism of Action: PI3K delta inhibitor, which helps to inhibit the […]